HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Jul 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new test called a semiquantitative multiplex PCR assay to see if it can help doctors quickly identify if critically ill patients have hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). The goal is to find out if this new test can provide results faster than traditional methods, which could help doctors start the right treatment sooner and reduce unnecessary medications within the first 24 hours after pneumonia is suspected.

To be eligible for this trial, participants must be critically ill with signs suggesting they may have HAP or VAP, and they need to be able to undergo a specific procedure to collect lung samples within an hour of suspicion. Additionally, they should expect to live for at least 48 hours. The trial is open to all adults aged 65 and older, but pregnant individuals or those already in another trial cannot participate. Participants will need to provide written consent to join the study, and they can expect to receive close monitoring and care throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Suspicion of HAP/VAP (clinical/radiological/laboratory criteria);
• • Availability to perform tracheal aspirates or broncoalveolar lavage within 1 hour from clinical suspicion
• • Life expectancy ≥ 48 hours
• • Signed written informed consent.
• Exclusion Criteria:
• • Pregnancy,
• • Concomitant participating in other interventional trial
• • Refusal to sign informed consent